medigraphic.com
Colegio de Medicina Interna de México.

2013, Number 1

<< Back Next >>

Med Int Mex 2013; 29 (1)

Alterations of the QTc in patients with alcohol withdrawal and delirium tremens

Jalpilla BM, Ayala VG, Elizalde BCI, Cabrera MJL, Navarrete CJI, Rodríguez HA

Language: Spanish
References: 35
Page: 5-12
PDF size: 187.23 Kb.


ABSTRACT

Background: In the SAA and delirium tremens benzodiazepines are the treatment of choice, prevents seizures and delirium tremens, still 5%develop delirium tremens, their symptoms are decreased by haloperidol, but may prolonged QT can there fore requires an adequate selection of patients to avoid lethal electrocardiographic changes.
Objective: To determine whether haloperidol in patients with SAA and delirium tremens prolonged QTc.
Materialand Methods: Cohort, observational, longitudinal, prospective study in Mexican patients diagnosed with alcohol withdrawal and delirium tremens. ECG is taken and measured baseline QTc, initiate treatment with diazepam, and only those who develop delirium tremens haloperidol dose response is initiated, provided they meet the criteria for inclusion and exclusion, and perform a second ECG after use haloperidol.
Results: in patients with baseline QTc haloperidol 40.91ms+/ -0.951(CI40.59-41.24) v /s41.11ms+ /1132(CI40.73-41.50) p = 0.168. QTc later in the benzodiazepine group of patients was not prolonged, in the haloperidol group was prolonged in 17 patients, x2 =0.0001. The correlation coefficient between the duration of non-stop months of in take and the prolongation of QTc rho: 0.523,p =0.001,r2:0.2735. The association between dose of haloperidol in relation to the prolongation of QTc is 50 mg daily, rho 0.758, p: 0.0001, CI (60.11-40.63), and r2:0.5745.
Conclusion: Haloperidol IV in the SAA and delirium tremens prolongs the QT from 50 mg daily


REFERENCES

  1. Ashok J, Newton E. Withdrawal syndromes. CME, 2005 noviembre15.

  2. Kosten TR, O´Connor PG. Management of drug and alcohol withdrawal. New England J Medicine 2003;348:1786-1795.

  3. Bayard M, Mcintyre J, Hill KR, Woodside J. Alcohol withdrawal syndrome. AmFam Physician 2004;69:1443-1450.

  4. Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis and management. Clin J Am SocNephrol 2008;3:208-225.

  5. Worby PA, Organista KC. Alcohol use and problem drinking among male mexican and central american immigrant laborers. Hispanic Journal of Behavioral Sciences 2007;29(4):413-455.

  6. Sarff MC, Gold JA. Alcohol withdrawal syndromes in the intensive care unit. Crit Care Med 2010;38(9).

  7. Alcohol Alert number 72, April 2007. Alcohol Research & health 2007; 30 (1).

  8. Comisión Clínica de la Delegación del Gobierno para el Plan Nacional sobre Drogas: Informe sobre Alcohol. Ministerio de Sanidad y Consumo. Madrid, 2007. En: Guías de recomendaciones del alcohol, España.

  9. Mayo-Smith M. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline and evidence-based practice guideline. JAMA 1997; 278: 144-151.

  10. D'Onofrio G, Rathlev NK, Ulrich AS, Fish SS, Freedland ES. "Lorazepam for the prevention of recurrent seizures related to alcohol". N Engl J Med 1999; 340 (12): 915–9.

  11. Vabret F. Alcohol withdrawal syndrome: managing and treatment protocol. Rev Prat 2006; 56(10):1093-9.

  12. Dissanaike S, Halldorsson A, Frezza EE, Griswold J. An ethanol protocol to prevent alcohol withdrawal syndrome, J Am CollSurg 2006;203(2):186-91.

  13. Vabret F. Alcohol withdrawal syndrome: managing and treatment protocol. Rev Prat 2006;56(10):1093-9

  14. Saitz R. Introduction to alcohol withdrawal. Alcohol Health & Research World 1998; 22: 5- 12.

  15. Adinoff B. Double-blind study of alprazolam, diazepam, clonidine and placebo in the alcohol withdrawal syndrome. Alcohol ClinExp Res 1994; 18: 873-878.

  16. Hollbrook A, Crowther R, Lotter A, et al. Meta-analysis of benzodiacepine use in the treatment of acute alcohol withdrawal. CMAJ 1999; 160: 649-655.

  17. Ntais C, Pakos E, Kyzas P, Ioannidis JP. Benzodiazepines for alcohol withdrawal. Cochrane Database Sist Rev 2005; (3): CD005063.

  18. Amato L, Minozzi S, Vecchi S, Davoli M. Cochrane Database Sist Rev 2010; (3): CD005063

  19. Saitz R, O´Malley S. Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Med Clin North Am 1997; 81: 881-907.

  20. Mayo –Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med 2004;164:1405-1412.

  21. Williams D, Mc Bride AJ. The drug treatment of alcohol withdrawal symptoms: a systematic review. Alcohol Alcohol 1998; 33: 103-115.

  22. Thompson WL. Management of alcohol withdrawal syndromes. Arch Intern Med. 1978; 138: 278-83.

  23. Foy A, Kay J, Taylor A. The course of alcohol withdrawal in a general hospital. QJM 1997; 90: 253-61.

  24. Cuculi F, Kobza R, Ehmann T, Erne P. ECG changes among patients with alcohol withdrawal seizures and delirium tremens. Swiss Med Wkly 2006; 136:223–7.

  25. Corović N, Duraković Z, Misigoj-Duraković M. Dispersion of the Corrected QT an JT interval in the electrocardiogram of alcoholic patients. Alcoholism Clinical and Experimental Research 2006; 30: 150-154.

  26. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G. QT interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28-34.

  27. Bär KJ, et al. Reduced baroreflex sensitivity in acute alcohol withdrawal syndrome an in abstained alcoholics. Drug Alcohol Depend 2006; 85: 66-74.

  28. Bär KJ, Boettger MK, Koschke M, Boettger S, Grotelüschen M, Voss A, Yeragani VK. Increased QT interval variability index in acute alcohol withdrawal. Drug Alcohol Depend 2007; 89: 259-266.

  29. Krasemann T. QT prolongation in the newborn and maternal alcoholism. Cardiol Young 2004; 14: 565-566.

  30. Subbalakshmi NK, Adhikari PMR, SathyanarayanaRao KN, Jeganathan PS. influencing factors of QTc among the clinical characteristics in type 2 diabetes mellitus Diabetes Res ClinPract 2010, doi:10.1016/j.diabres.2010.03.001.

  31. Yokoyama A, Ishii H, Takagi T, Hori S, Matsushita S, Onishi S, Katsukawa F, Takei I, Kato S, Maruyama K, et al. Prolonged QT interval in alcoholic autonomic nervous dysfunction. Alcohol ClinExp Res 1992; 16: 1090-1092.

  32. Tisdale JE, Kambe JC, Chow MSS, et al. The effect of haloperidol on ventricular fibrillation threshold in pigs. Pharmacol- Toxicol 1991;69:327–9.

  33. Sharma ND, Rosman HS, Padhi ID, et al. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998;81:238–40.

  34. Jarque A, González-Reimers E, Rodríguez-Moreno F, Santolaria, F, López-Lirola A, Ros R et al. Prevalence and mortality of heavy drinkers in a general medical hospital unit. Alcohol AlcoholOxfor Journal 2001; 36:335-338.

  35. Kotaro Hatta, MD et al. The Association Between Intravenous Haloperidol and Prolonged QT Interval. J ClinPsychopharmacol, June 2001Vol 21/No 3 257-261.




2020     |     www.medigraphic.com